👍_老虎社区_美港股上老虎

TKangWM
2021-11-04

👍

U.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill

Britain became the first country to approve Merck & Co’s Covid-19 antiviral pill, with the nation’s

U.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":846032515,"tweetId":"846032515","gmtCreate":1636034485136,"gmtModify":1636034587425,"author":{"id":3582197285087556,"idStr":"3582197285087556","authorId":3582197285087556,"authorIdStr":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/846032515","repostId":1167697278,"repostType":2,"repost":{"id":"1167697278","kind":"news","pubTimestamp":1636025569,"share":"https://www.laohu8.com/m/news/1167697278?lang=&edition=full","pubTime":"2021-11-04 19:32","market":"us","language":"en","title":"U.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1167697278","media":"Bloomberg","summary":"Britain became the first country to approve Merck & Co’s Covid-19 antiviral pill, with the nation’s ","content":"<p>Britain became the first country to approve Merck &amp; Co’s Covid-19 antiviral pill, with the nation’s drug regulator describing the treatment as safe and effective.</p>\n<p>The U.K.’s Medicines and Healthcare products Regulatory Agency authorized the drug, molnupiravir, for use in people with mild to moderate Covid and at least one risk factor for developing severe illness, the regulator said in a statement Thursday.</p>\n<p>Merck shares rose 2% in premarket U.S. trading.</p>\n<p><img src=\"https://static.tigerbbs.com/228503f62c7823fd2b8b78316babd5e6\" tg-width=\"847\" tg-height=\"622\" width=\"100%\" height=\"auto\"></p>\n<p>Boris Johnson’s government plans to focus on antiviral treatments at the same time as rolling out boosters to bolster immunity levels as winter approaches. The U.K. has already announced deals to secure two new Covid treatments: 480,000 courses of Merck’s pill and 250,000 courses of Pfizer Inc.’s PF 07321332/ritonavir.</p>\n<p>Coronavirus infections in England reached their highest level yet in October, based on a large study published Thursday. While hospitalizations and deaths remained low, the React-1 study led by Imperial College London recorded the highest prevalence of cases since the research began in May 2020. Covid infections among study participants increased to 1.72%, or one in 58 people, more than double the level in the previous month’s report.</p>\n<p>Based on the clinical trial data, Merck’s pill is most effective when taken during the early stages of infection, the regulator said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-04 19:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-04/u-k-drug-regulator-is-first-to-approve-merck-s-covid-19-pill?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Britain became the first country to approve Merck & Co’s Covid-19 antiviral pill, with the nation’s drug regulator describing the treatment as safe and effective.\nThe U.K.’s Medicines and Healthcare ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-04/u-k-drug-regulator-is-first-to-approve-merck-s-covid-19-pill?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-04/u-k-drug-regulator-is-first-to-approve-merck-s-covid-19-pill?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167697278","content_text":"Britain became the first country to approve Merck & Co’s Covid-19 antiviral pill, with the nation’s drug regulator describing the treatment as safe and effective.\nThe U.K.’s Medicines and Healthcare products Regulatory Agency authorized the drug, molnupiravir, for use in people with mild to moderate Covid and at least one risk factor for developing severe illness, the regulator said in a statement Thursday.\nMerck shares rose 2% in premarket U.S. trading.\n\nBoris Johnson’s government plans to focus on antiviral treatments at the same time as rolling out boosters to bolster immunity levels as winter approaches. The U.K. has already announced deals to secure two new Covid treatments: 480,000 courses of Merck’s pill and 250,000 courses of Pfizer Inc.’s PF 07321332/ritonavir.\nCoronavirus infections in England reached their highest level yet in October, based on a large study published Thursday. While hospitalizations and deaths remained low, the React-1 study led by Imperial College London recorded the highest prevalence of cases since the research began in May 2020. Covid infections among study participants increased to 1.72%, or one in 58 people, more than double the level in the previous month’s report.\nBased on the clinical trial data, Merck’s pill is most effective when taken during the early stages of infection, the regulator said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1087,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

U.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill

评论（1）

热议股票